Quick Facts

• Addresses: Neurocysticercosis and hydatid disease.
• Supports: The management of specific parasitic worm infections.
• Contributes to: Symptom relief related to certain tapeworm infestations.

---

Altec is a prescription medication approved for the management of two specific parasitic conditions: neurocysticercosis and hydatid disease.

Neurocysticercosis is a condition associated with the larval form of the Taenia solium (pork tapeworm). For this condition, treatment with Altec may help address the infestation and support overall clinical status. Hydatid disease, or cystic echinococcosis, is related to the larval form of the Echinococcus granulosus (dog tapeworm) and involves cyst formation in organs. Altec serves as an option for helping to manage this disease.

In addition to these primary indications, Altec is used in the management of other systemic infections caused by parasitic worms, which may help to relieve associated gastrointestinal symptoms.

Eligibility Map: Who Can and Cannot Use Altec — Official Regulatory Information

The use of Altec is contraindicated in several specific populations according to official regulatory labeling. Use is strictly prohibited for pregnant women and in patients with a known hypersensitivity to any of its four active components (Albendazole, Ambroxol, Guaifenesin, Terbutaline), or to benzimidazole-related compounds. Absolute non-eligibility also applies to individuals with active liver disease and certain severe cardiovascular conditions, such as tachyarrhythmias.

Use is generally not recommended for children under two years of age or for lactating women. Eligibility is further restricted for patients with severe renal or hepatic impairment, necessitating special monitoring. Additional caution is mandated for individuals with pre-existing ischemic heart disease, uncontrolled hyperthyroidism, or uncontrolled diabetes mellitus, as the eligibility profile defines clear boundaries for who can and cannot use the drug.

Eligibility Classifications (High-Level)

Classification	Examples of Affected Populations
Absolute Contraindication	Pregnant women, Hypersensitivity, Active Liver Disease
Not Recommended	Children under two years, Lactating women
Restricted Use/Caution	Severe Renal/Hepatic Impairment, Ischemic Heart Disease

Connection to the overall eligibility profile

Regulatory documents define Altec's eligibility by establishing clear criteria based on reproductive status, age, organ function, and cardiovascular/metabolic health. This ensures the medicine is only administered within the population restrictions and prohibitions outlined in government-approved labeling.

Interactions with Other Medicines and Products

This section summarizes the officially documented interactions for Altec (alteplase), based strictly on information provided in government regulatory documents.

Altec's interaction profile is primarily defined by pharmacodynamic effects that increase the risk of bleeding rather than by changes to its drug levels.

---

Documented Interaction Categories

Category	Relevant Substances or Classes
Hemorrhagic Risk	Anticoagulants (e.g., Heparin), Antiplatelet Agents (e.g., Aspirin)
Angioedema Risk	Angiotensin-Converting Enzyme (ACE) Inhibitors

---

Official Regulatory Statements on Combinations

• Increased Bleeding Risk: Concomitant use of medicines that inhibit blood coagulation or platelet function significantly elevates the risk of hemorrhage. The regulatory label emphasizes close clinical monitoring when Altec is administered alongside anticoagulants or antiplatelet agents.
• Angioedema: Co-administration with ACE Inhibitors may increase the risk of developing orolingual angioedema.
• Infusion Restrictions: No other medications should be added to the infusion solutions containing Altec.

Pharmacokinetic Interactions

Official regulatory documents do not explicitly document clinically significant interactions based on changes to Altec's systemic exposure (AUC/Cmax) via CYP enzymes or drug transporters (e.g., P-gp). Altec's rapid clearance minimizes the potential for such pharmacokinetic drug interactions. Likewise, interactions with food, alcohol, or specific herbal products are not detailed in the official interaction sections.

How Altec Works

---

The overall physiological effect of this combination is driven by three distinct mechanistic domains. The bronchodilator component acts as a selective agonist of the boldsymbolbeta2-adrenergic receptors on bronchial smooth muscle cells. This interaction triggers the cAMP cascade, leading to the relaxation of bronchial smooth muscle and a resulting increase in the caliber of the air passages.

Concurrently, the respiratory secretion modulators exert a dual-action mechanism. The expectorant component initiates a gastro-pulmonary reflex to increase the volume and hydration of airway secretions, while the mucolytic component stimulates surfactant release and disrupts the chemical structure of mucus fibers. This synergistic effect reduces the viscosity and adhesion of the secretions, facilitating their mobility for clearance.

Separately, the anti-parasitic component operates via selective inhibition of the parasitic boldsymbolbeta-Tubulin subunit, preventing its polymerization into microtubules. This disruption impairs cellular structure and prevents glucose absorption, leading to the metabolic depletion and immobilization of the target helminth.

Official Administration Guidelines for Altec

The administration of Altec, a combination product, is governed by distinct requirements for its active components, necessitating two primary usage patterns. The sole approved route of administration is oral for both the tablet and liquid formulations.

Key Usage Regimens

Component/Indication	Standard Adult Regimen	Frequency & Timing
Albendazole Component (Parasitic)	400 mg twice daily (for ≥60 kg) or 15 mg/kg/day divided twice daily (for <60 kg).	Twice Daily (BID), must be taken with food (fatty meal).
Respiratory Component (Symptomatic)	10 mL to 20 mL of the oral liquid formulation.	Thrice Daily (three times per day).

Administration Conditions and Duration

This regimen is highly structured by required administration conditions. The tablet component may be crushed or chewed and swallowed with water if the whole tablet cannot be taken. The requirement to take the anti-parasitic component with a fatty meal is essential for proper systemic absorption.

The duration is strictly time-bound: Neurocysticercosis requires 8 to 30 days of treatment. Hydatid disease is treated in a cyclic regimen involving 28 days of dosing followed by a 14-day drug-free interval, repeated up to three times. For specific parasitic indications, the usage protocol officially includes the requirement for concomitant administration of steroids and anticonvulsant medications.

Research Evidence / Overview of Studies for Altec

Evidence for Use in Neurocysticercosis

Research for neurocysticercosis (NCC) is primarily based on Randomized Controlled Trials (RCTs) and systematic reviews examining patients with active lesions in the brain parenchyma. These studies focus on neurological outcomes like seizure frequency and radiological changes, such as the disappearance or reduction of cysts on CT or MRI scans. Studies report how the number of viable cysts measured by imaging evolved, and some findings described patterns related to lower seizure rates and cyst disappearance being measured. However, findings were mixed when examining the overall long-term seizure recurrence rate in some systematic reviews.

Evidence for Use in Hydatid Disease

The evidence base for hydatid disease focuses on the antihelmintic component's use against the larval forms of the Echinococcus granulosus parasite. Studies, including RCTs, examined outcomes related to cyst viability and monitored changes in cyst size and number via imaging. Research described patterns related to lower viability being measured and the subsequent absence of recurrence being monitored over time when studied before or after surgical procedures. However, the evidence quality varies across studies, in part because the disease is complex.

Evidence for Symptomatic Respiratory Relief

The symptomatic use of Altec is based on the combination of its three respiratory components: a bronchodilator, a mucolytic agent, and an expectorant. This was evaluated in shorter clinical studies and Phase IV trials focused on conditions where productive cough and temporary breathing difficulties co-exist. Outcomes monitored over defined time intervals examined measurements of cough intensity, frequency, and ease of expectoration in the observed populations. Research indicates these components were studied to assess short-term symptom patterns.

Long-Term Research and Subgroup Data

Observation periods in some neurocysticercosis trials have extended up to 12 years or more to track long-term outcomes like freedom from seizures. Research describes that patterns of long-term health, including continued neurological symptoms, were observed by researchers in a high proportion of individuals years after the initial treatment was completed. Specific research includes both adult and pediatric patients, but data for certain subgroups (e.g., extraparenchymal cysts) remain insufficient, and evidence for the respiratory components is limited to the short-term treatment phase.

What is Still Uncertain About Altec Research

Several areas of uncertainty remain: the published peer-reviewed research for the four-component combination (including Albendazole) specific to respiratory outcomes is limited; findings for long-term reduction in seizure recurrence are mixed; and research does not definitively determine the optimal treatment course or duration for all presentations of parasitic disease.

Key Studies & References

1. The effect of albendazole treatment on seizure outcomes in patients with symptomatic neurocysticercosis
2. Short course of albendazole therapy for neurocysticercosis: A prospective randomized trial comparing three and eight days of treatment and comparing its effectiveness with symptomatic treatment
3. Albendazole for the treatment of human echinococcosis: a review of comparative clinical trials

Common questions about Altec (FAQ)

Q: What is the maximum number of days I can take Altec?

Official administration guidelines outline specific treatment durations for the anti-parasitic component. For neurocysticercosis, treatment usually lasts 8 to 30 days. For hydatid disease, the regimen is cyclic, involving up to three 28-day dosing periods separated by drug-free intervals. The maximum duration for the symptomatic respiratory component is not explicitly defined in the official labeling.

---

Q: What does the 15 mg/kg/day dosing mean for a child who weighs 50 kg?

Official product information for the anti-parasitic component provides weight-based dosing guidance. For a patient who weighs 50 kg, the prescribed 15 mg/kg/day regimen results in a total daily amount of 750 mg of the component. This daily total is often divided into doses taken twice daily, and the daily maximum amount for this component is generally 800 mg.

---

Q: What should I do if I forget a dose of Altec?

According to the official product information, if a dose is missed, it may be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose is usually skipped, and the regular schedule is continued. It is advised that two doses are not taken at the same time to compensate for a missed dose.

---

Q: Can I take Altec with an antacid for stomach upset?

Regulatory documents primarily focus on the risk of interactions with anti-clotting medicines and certain blood pressure medicines. The official label does not explicitly list an interaction with antacids. Furthermore, regulatory documents state that interactions with general food products, alcohol, or specific herbal products are not detailed in the official interaction sections.

---

Q: What is the proper way to take the oral liquid (syrup) form of Altec?

The oral liquid formulation is taken by mouth at the volume prescribed by a healthcare provider. The dose should be measured carefully to ensure accuracy, which is standard practice for liquid medicines. Unlike the tablet, which may be crushed or chewed, the official labeling provides specific instructions for dosing the liquid formulation based only on the required volume.

---

Q: What are the common side effects that are specific to the anti-parasitic component (Albendazole)?

Studies and official information indicate that common side effects associated with the anti-parasitic component include gastrointestinal issues like nausea, vomiting, and abdominal pain. Other common effects reported in clinical trials include headache and temporary hair loss (reversible alopecia). Very common effects, occurring in 10% or more of patients, include headache and increases in liver enzyme levels.

---

Q: What is the maximum daily dose of the bronchodilator component?

Official labeling for this combination product defines the maximum daily amount of the bronchodilator component. The largest amount for the bronchodilator component, Terbutaline, is generally 15 mg within a 24-hour period, based on the three-times-per-day regimen.

How to Store and Dispose of Altec

The storage and disposal instructions for this medicine are defined by official regulatory requirements to ensure product quality and public safety.

Storage Requirements

Condition	Regulatory Requirement
Temperature	Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Protection	Keep out of the reach and sight of children. Protect from light and excessive moisture.
Handling Rule	Do not freeze the oral liquid (suspension) formulation. Keep the container tightly closed in its original packaging.

Disposal Instructions

Expired or unused Altec must be disposed of according to local regulations. Regulatory guidelines advise against discarding the medicine in wastewater (sinks or toilets) unless the official product labeling specifically directs this action. The preferred method for discarding unused medicine is through a community drug take-back program.